Type 2 diabetes may be an indication of pancreatic cancer

Washington D.C. [USA] Jun 19(ANI): Turns out, a recent-onset type 2 diabetes may be early expression of pancreatic cancer.

A new study published by Oxford University Press indicated that the recent-onset diabetes was associated with a 2.3-fold greater increase in risk of pancreatic cancer than long-standing diabetes.

Pancreatic cancer is one of the most fatal cancers, with a five-year survival rate of only 8 percent because majority pancreatic cancer patients are diagnosed at a late stage.

Diabetes is linked to both a risk factor for and a consequence of pancreatic cancer. The prevalence of diabetes among pancreatic cancer patients is unusually high as compared to other cancers.

The majority of the diabetes patients with pancreatic cancer are diagnosed with diabetes less than three years before being diagnosed with cancer. Among the patients undergoing pancreaticoduodenectomies (the surgical operation often used to try to remove pancreatic tumors), almost half have no diabetes postoperatively.

The researchers examined the association between recent-onset diabetes and pancreatic cancer in a prospective study of African Americans and Latinos, two minority populations with high diabetes risk.

Diabetes was found to be associated with an approximately twofold increased risk of pancreatic cancer. Importantly, the researchers demonstrated that the association of recent-onset diabetes with pancreatic cancer incidence was evident in African- Americans and Latinos.

The findings support the hypothesis that recent-onset diabetes in pancreatic cancer is a manifestation of developing pancreatic cancer.

“This striking relationship between recent-onset diabetes is unique to pancreatic cancer, and is not seen in breast, prostate and colorectal cancer in the cohort,” said one of the paper’s authors, Wendy Setiawan.

The study is published in Journal of the National Cancer Institute. (ANI)

  • Related Posts

    Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

    Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

    HC denies bail to pharma company owner for manufacturing spurious drugs

    Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

    Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

    Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

    Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

    Illegally stocked drugs worth Rs 5.21 lakh seized

    Illegally stocked drugs worth Rs 5.21 lakh seized

    Patanjali and AIIMS Bhopal partner to develop holistic treatment solutions

    Patanjali and AIIMS Bhopal partner to develop holistic treatment solutions